Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from HOYA ( (JP:7741) ).
HOYA Corporation announced a strategic move to transfer its endoscope business in Japan to a newly established wholly owned subsidiary, PENTAX Medical Corporation, through a simplified absorption-type company split effective May 1, 2026. This restructuring aims to enhance the business’s growth by allowing PENTAX Medical to make more focused decisions on product development, sales, and compliance, aligning with the industry’s specific needs and potentially strengthening HOYA’s market position.
The most recent analyst rating on (JP:7741) stock is a Buy with a Yen22575.00 price target. To see the full list of analyst forecasts on HOYA stock, see the JP:7741 Stock Forecast page.
More about HOYA
HOYA Corporation operates in the fields of Electronics, Imaging, Health Care, and Medical, with a focus on manufacturing, sales, and associated services. The company is involved in the development, manufacture, and sales of medical equipment through its subsidiary PENTAX Medical Corporation, which is part of its global endoscope business.
Average Trading Volume: 1,032,521
Technical Sentiment Signal: Hold
Current Market Cap: Yen5833.6B
Find detailed analytics on 7741 stock on TipRanks’ Stock Analysis page.